RxDoctor Payments DataLook up a doctor →

Catherine Broome, MD

Hematology & Oncology · Washington, DCNPI 1669470985

Payments from drug & device makers

$2,929,062in general payments, 2019–2025

Across 490 payments — averaging $5977.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bioverativ Therapeutics Inc.$927K
  • Argenx US, Inc.$333K
  • Sanofi US Services Inc.$319K
  • Sanofi$279K
  • AstraZeneca$276K
  • Acerta Pharma LLC$205K
  • plus $591K from 17 others
$114,263in research payments, 2019–2025

Across 29 payments — averaging $3940.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Rigel Pharmaceuticals, Inc.$104K
  • Bioverativ Therapeutics Inc.$5K
  • Sanofi$5K

What the payments were for

  • Consulting fees$268,07553%
  • Speaking & faculty fees$170,95334%
  • Travel & lodging$61,38312%
  • Food & beverage$3,3521%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,929,062 in reported general payments places this provider in the 90th percentile of 69 hematology & oncology providers in District of Columbia.

See all hematology & oncology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$62,708
Medicare patients
235
Services billed
500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate93$1,300,005
ImbruvicaIbrutinib52$736,140
PromactaEltrombopag Olamine16$323,549
BrukinsaZanubrutinib16$246,007
VenclextaVenetoclax12$185,765
EliquisApixaban48$60,531
XareltoRivaroxaban32$48,573
Fondaparinux Sodium12$20,047
Hydromorphone Hcl30$753
Hydroxyurea22$727
Warfarin Sodium15$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$275,965$1,300,00593 claims
NovartisPromacta$128,172$323,54916 claims
AbbVieVenclexta$35$185,76512 claims
Johnson & JohnsonXarelto$16$48,57332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 69 hematology & oncology providers in District of Columbia.

Other hematology & oncology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →